AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study

(Bloomberg) -- AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.